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Accepted 7 March 2012AbstractObjective: Adiponectin plays a role in obesity, lipid metabolism, and anti-inflammation. Women with polycystic ovary syndrome (PCOS) are
also at risk for dyslipidemia. Therefore, we investigated the association between adiponectin levels and the lipid profile including high-density
lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TGs) in women with PCOS and contemplated
what role adiponectin might play in dyslipidemia with PCOS.
Materials and Methods: We recruited 118 young Taiwanese women with PCOS. The women enrolled were not taking any medication and those
with other systemic diseases of nonovarian origin, which could have affected the hypothalamicepituitaryeovarian axis, were excluded. The
serum lipid profile, metabolic and hormonal parameters, and adiponectin were measured. The lipid profile and adiponectin were analyzed and
adjusted for age, body mass index (BMI), homeostasis model assessment-insulin resistance (HOMA-IR), and sex hormone-binding globulin
(SHBG).
Results: In a simple linear regression, adiponectin was significantly inversely related to LDL-C and TGs, but positively related to HDL-C (all
p < 0.001) after logarithmic transformation. In the multiple linear regression, adiponectin was significantly related to HDL-C ( p < 0.001)
independent of age, BMI, HOMA-IR, and SHBG after logarithmic transformation. Using a logistic regression, the odds ratio was 0.088 between
the association of increased adiponectin and abnormal HDL-C (50 mg/dL).
Conclusions: We demonstrated that adiponectin is an independent biomarker that is positively and evidently related to HDL-C and TGs in
women with PCOS. Hypoadiponectinemia may be a useful marker of dyslipidemia in women with PCOS.
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Polycystic ovary syndrome (PCOS), a syndrome of ovarian
dysfunction, is associated with oligo- and/or anovulation,
clinical and/or biochemical signs of hyperandrogenism, and
polycystic ovaries [1]. PCOS is considered to be one of the
most common endocrinopathies in fertile women [2] and even
a variant of metabolic syndrome [3]. A close relationship
between PCOS and insulin resistance is recognized [4,5].
Whether women with PCOS are under an increased risk ofcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Cardiovascular risk factors including dyslipidemia, hyper-
androgenemia, and markers of inflammation in women with
PCOS were demonstrated [2]. As to dyslipidemia, a lower
serum level of high-density lipoprotein cholesterol (HDL-C)
in women with PCOS compared to those without PCOS was
documented [6]. HDL-C is the best potential lipoprotein
predictor of morbidity and mortality in patients with CVD
[7,8].
Adiponectin is exclusively produced by adipocytes [9e12].
The adiponectin gene is located on chromosome 3q37, as is
a locus for diabetes susceptibility, and encodes a secretory
protein from adipose tissue, which accounts for 0.01e0.05%
of the total serum protein [9,13]. In both obesity and type-2
diabetes mellitus, serum adiponectin levels are significantly
lower in affected groups than in healthy groups [14]. It was
also proposed that decreased adiponectin levels were related to
coronary artery disease (CAD) compared to matched controls
[13]. Adiponectin may play a role as an anti-inflammatory
vasoprotective adipokine [15].
Recently, several studies found that serum adiponectin
levels are significantly decreased in PCOS groups compared to
control groups [16,17]. However, no further study on the
relationship between adiponectin and the lipid profile in PCOS
was published. In the present study, we comprehensively
explored the association between adiponectin and HDL-C in
young Taiwanese women with PCOS prior to treatment.
Materials and methodsParticipantsFrom October 2004 to May 2006, we recruited 118 young
Taiwanese women with PCOS who had received no medica-
tion for 6 months prior to enrollment in this study. They visited
our reproductive endocrinology clinic and presented with
irregular menstrual cycles and/or clinical hyperandrogenism.
The present study was approved by the Institutional Review
Board of National Taiwan University Hospital, and the
patients and/or their parents all signed an informed consent
form prior to data collection. All women with PCOS enrolled
in this study were diagnosed with two of the three criteria
proposed at the Rotterdam revised consensus meeting [4],
including oligomenorrhea or amenorrhea, clinical hyper-
androgenism and/or hyperandrogenemia, and polycystic
ovaries as visualized by pelvic ultrasonography (US), as
described in our previous study [18].
Oligomenorrheawas defined as fewer than eight spontaneous
menstrual cycles per year and with an interval of greater than 45
days between cycles. The definition of hyperandrogenism was
an elevated serum total testosterone level of >0.8 ng/mL with
persistent acne or hirsutism (a Ferriman and Gallwey score of
>8). Visualized polycystic ovaries meantmore than 12 follicles,
2e9mm in diameter, per ovary by transvaginal US or an ovarian
volume of 10 cm3 by transabdominal US with a distended
bladder in virginal women. Exclusion of other etiologies of
nonovarian origin included hyperprolactinemia, thyroiddysfunction, Cushing’s syndrome, congenital adrenal hyper-
plasia, adrenal tumors, virilizing ovarian tumors, autoimmune
diseases, malignancies, central nervous system diseases,
a current or previous pregnancy in the past year, and prescription
of oral contraceptives or other medications that could affect
the hypothalamicepituitaryeovarian axis within the previous
6 months.Data collectionBlood samples were collected from these women under
spontaneous menstrual cycles between the 3rd and 7th days and
between 08:00 and 10:00 after an overnight fast. In women
without menstruation for longer than 3 months, blood samples
were collected without hormone-induced withdrawal bleeding
under pelvic US detection, and the serum progesterone level
was also determined. If the serum estradiol level exceeded
150 pg/mL, the serum progesterone exceeded 2 ng/mL, or
a dominant follicle was present on US, the sampled blood was
discarded. Patients whose blood samples had been abandoned
were then asked to measure their basal body temperature in
order to detect if spontaneous ovulation had occurred in this
discarded cycle. We subsequently collected blood samples
again during the next cycle in 2e3 weeks following
menstruation.
Blood samples were processed within 30 minutes of
collection. Blood glucose and insulin samples were kept at
4C and analyzed on the day of sampling. Prior to the assay,
serum and plasma were separated into aliquots and frozen at
70C. Anthropometric, pelvic US, and blood-pressure
measurements were performed on the day of venipuncture.
The body mass index (BMI) was calculated by the weight (in
kilograms) divided by the height (in meters) squared.Assay methodsWe used an autoanalyzer (Toshiba TBA-120FR Chemistry
Analyzer; Tokyo, Japan) to measure plasma glucose levels. We
measured serum concentrations of total cholesterol, low-
density lipoprotein cholesterol (LDL-C), HDL-C, and
triglycerides (TGs) with a biochemical autoanalyzer (Toshiba
TBA-200FR). We measured insulin levels by a microparticle
enzyme immunoassay using an AxSYM system (Abbott
Laboratories, Dainabot, Tokyo, Japan). The degree of insulin
resistance [homeostasis model assessment-insulin resistance
(HOMA-IR) ¼ (glucose  0.05551)  insulin/22.5] was
estimated, where the levels of insulin and glucose are
expressed in mU/mL and mg/dL, respectively [19].
We used chemiluminescence (Vitros Eci; Ortho-Clinical
Diagnostics, Rochester, NY, USA) to measure directly the
concentrations of serum follicle-stimulating hormone (FSH),
luteinizing hormone (LH), estradiol, and progesterone. We
measured the levels of serum sex hormone-binding globulin
(SHBG) by electrochemiluminescence (Elecsys 2010; Roche
Diagnostics, Mannheim, Germany). We measured levels of
serum total testosterone and dehydroepiandrosterone sulfate
(DHEA-S) by a radioimmunoassay (RIA; Diagnostic Systems
Table 1
Clinical and hormonal characteristics of 118 Taiwanese women with
polycystic ovary syndrome.
No. (%) Mean  SE Range






BMI (kg/m2) 24.23  0.55 15.43e40.70
<18.50 21 (17.80) 15.43e18.49
18.50e23.99 48 (40.68) 18.75e24.88
24.00e26.99 11 (9.32) 25.07e29.43
27.00 38 (32.20) 30.08e40.70
FSH (mIU/mL) 5.56  0.11 8.87e2.44
LH (mIU/mL) 11.99  0.62 34.50e1.61
Estradiol (pg/mL) 42.53  3.55 413.00e15.42
DHEA-S (mg/dL) 286.11  6.36 627.00e62.70
Fasting glucose (mg/dL) 84.52  1.12 66e132
Fasting insulin (mU/mL) 13.76  1.20 0.2e62.5
HOMA-IR 3.09  0.32 0.04e20.20
LDL-C (mg/dL) 106.96  2.72 44e193
HDL-C (mg/dL) 47.24  4.35 27e94
Total cholesterol (mg/dL) 190.86  3.17 114e281
Total triglyceride (mg/dL) 87.24  4.71 28e336
SHBG (nmol/L) 38.1  2.1 9.9e124.0
Total testosterone (ng/mL) 1.00  0.03 0.4e2.1
Adiponectin (mg/mL) 1.95  0.09 0.61e6.02
BMI ¼ body-mass index; DHEA-S ¼ dehydroepiandrosterone sulfate;
FSH ¼ follicle-stimulating hormone; HDLC ¼ high-density lipoprotein-
cholesterol; HOMA-IR ¼ homeostasis model assessment of insulin resis-
tance; LDL-C ¼ low-density lipoprotein cholesterol; LH ¼ luteinizing
hormone; SE ¼ standard error; SHBG ¼ sex hormone-binding globulin.
Fig. 1. Linear regression curve of logarithmically transformed (ln) HDL-C as
the dependent variable in Taiwanese women with polycystic ovary syndrome
(r ¼ 0.617, p < 0.0001). HDL-C ¼ high-density lipoprotein cholesterol.
Fig. 2. Linear regression curve of logarithmically transformed (ln) LDL-C as
the dependent variable in Taiwanese women with polycystic ovary syndrome
(r ¼ 0.346, p < 0.001). LDL-C ¼ low-density lipoprotein cholesterol.
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enzyme-linked immunosorbent assay (ELISA) (Human Adipo-
nectinELISAKit, B-Bridge International, Sunnyvale,CA,USA)
according to themanufacturer’s instructions to measure levels of
serum adiponectin [20]. The intra- and interassay coefficients of
variation of the aforementioned assays were all <10%.Fig. 3. Linear regression curve of logarithmically transformed (ln) TGs as the
dependent variable in Taiwanese women with polycystic ovary syndrome
(r ¼ 0.473, p < 0.0001). TG ¼ triglyceride.
Table 2
Regression of logarithmically transformed (ln) lipid levels with age and ln HOMA-IR, adiponectin, SHBG, and BMI among 118 Taiwanese women with polycystic
ovary syndrome.
ln HDL-C ln LDL-C ln TG
r SE p r SE p r SE p
Age 0.008 0.004 0.928 0.406 0.005 <0.0001 0.327 0.009 <0.001
ln BMI 0.478 0.076 <0.0001 0.412 0.105 <0.0001 0.525 0.170 <0.0001
ln HOMA-IR 0.398 0.019 <0.0001 0.371 0.025 <0.0001 0.567 0.039 <0.0001
ln SHBG 0.536 0.028 <0.0001 0.224 0.043 0.016 0.396 0.071 <0.0001
ln adiponectin 0.617 0.034 <0.0001 0.346 0.053 <0.001 0.473 0.088 <0.0001
BMI ¼ body-mass index; HDL-C ¼ high-density lipoprotein cholesterol; HOMA-IR ¼ homeostasis model assessment-insulin resistance; LDL-C ¼ low-density
lipoprotein cholesterol; SE ¼ standard error; SHBG ¼ sex hormone-binding globulin; TG ¼ total triglyceride.
586 C.-Y. Chang et al. / Taiwanese Journal of Obstetrics & Gynecology 51 (2012) 583e590Statistical analysesAll statistical analyses were performed using the statistical
software SPSS version 12.0.1C (SPSS Inc., Chicago, IL,
USA). Numeric variables are shown as the mean  standard
error (SE) and range, unless indicated otherwise. Due to
positively skewed distributions about the BMI, HOMA-IR,
HDL-C, LDL-C, TG, SHBG, and adiponectin, we first loga-
rithmically transformed those data and then used a simple
linear regression to calculate the regression coefficient
between the logarithmically transformed lipid profile param-
eters and other parameters, including age, logarithmically
transformed BMI (ln BMI), ln HOMA-IR, ln SHBG, and ln
adiponectin.
We used ln HDL-C, ln LDL-C, and ln TGs as the dependent
variables, and anthropometric and metabolic factors and ln
adiponectin as independent variables to perform forward
stepwise multiple linear regression models. We introduced
a multivariate regression analysis to assess the respective
relationships of ln HDL-C, ln LDL-C, and ln TGs with ln
adiponectin after adjusting for anthropometric and metabolic
factors. In the multiple linear model, age, ln BMI, ln HOMA-
IR, ln SHBG, and ln adiponectin were diagnosed by values of
the variance inflation factor (VIF) to avoid collinearity. A p
value of <0.05 was considered statistically significant.
Results
The mean age of the total 118 participants was
24.78  4.69 (range, 15e37) years. The basic characteristicsTable 3
Multiple regression analysis of ln HDL levels (mg/dl) with age, logarithmically tr
Taiwanese women with polycystic ovary syndrome.
Variable Model 1
r SE p r
Age (y) 0.139 0.003 0.054
Ln BMI (kg/m2) 0.102 0.104 0.360
Ln HOMA-IR 0.067 0.022 0.497
Ln SHBG (nmol/L) 0.283 0.033 0.003 0.3
Ln adiponectin (mg/mL) 0.489 0.041 <0.0001 0.4
R2 (0.690)2 ¼ 0.476
BMI ¼ body-mass index; HDL ¼ high-density lipoprotein; HOMA-IR ¼ homeos
hormone-binding globulin.of these participants are summarized in Table 1. Under
a simple linear regression, levels of ln adiponectin were
significantly correlated with that of ln HDL-C ( p < 0.0001,
Fig. 1), ln LDL-C ( p < 0.001, Fig. 2), and ln TGs
( p < 0.0001, Fig. 3) (Table 2).
Considering possible confounding factors to adiponectin,
we used multiple linear regression analyses and found that the
adiponectin level after logarithmic transformation was only
significantly related to the ln HDL-C level ( p < 0.0001)
compared to LDL and TGs after adjusting for age, ln BMI, ln
HOMA-IR, and ln SHBG (Tables 3e5, model 1). As to the
analysis of collinearity in the multiple linear model to predict
levels of HDL-C, values of the VIF for age, ln BMI, ln
HOMA-IR, ln SHBG, and ln adiponectin were 1.103, 2.625,
2.101, 1.798, and 1.615, respectively. Therefore, adiponectin
had no interactions with age, BMI, HOMA-IR, or SHBG.
After a forward stepwise multiple linear regression with ln
HDL-C as the dependent variable, we found that only ln
SHBG and ln adiponectin were significant in the multiple
regression model (Table 3, model 2). Consequently, we noted
that the HDL-C level was essentially dependent on both adi-
ponectin and SHBG levels.
With LDL-C as the dependent variable, age and ln BMI
were significant in the forward stepwise multiple linear
regression after adjusting for ln HOMA-IR, ln SHBG, and ln
adiponectin (data not shown). We then used a multiple linear
regression with LDL-C as the dependent variable, and found
that the LDL level was dependent on only age and adiponectin
did not affect the LDL level at all (Table 4, model 1). Although
only age and ln BMI were significant after the forwardansformed (ln) BMI, ln HOMA-IR, ln SHBG, and ln adiponectin among 118
Model 2 Model 3
SE p r SE p
0.126 0.003 0.074
14 0.028 <0.001 0.305 0.028 <0.001
67 0.036 <0.0001 0.498 0.037 <0.0001
(0.676)2 ¼ 0.457 (0.687)2 ¼ 0.472
tasis model assessment-insulin resistance; SE ¼ standard error; SHBG ¼ sex
Table 4
Multiple regression analysis of logarithmically transformed (ln) low-density lipoprotein levels (mg/dL) with age, ln BMI, ln HOMA-IR, ln SHBG, and ln adi-
ponectin among 118 Taiwanese women with polycystic ovary syndrome.
Variable Model 1 Model 2 Model 3
r SE p r SE p r SE p
Age (y) 0.322 0.005 <0.001 0.314 0.005 <0.001 0.347 0.005 <0.0001
Ln BMI (kg/m2) 0.170 0.159 0.194 0.259 0.122 0.011
Ln HOMA-IR 0.187 0.033 0.111 0.261 0.026 0.007
Ln SHBG (nmol/L) 0.048 0.050 0.657
Ln adiponectin (mg/mL) 0.102 0.062 0.323 0.127 0.059 0.203 0.134 0.057 0.164
R2 (0.543)2 ¼ 0.295 (0.528)2 ¼ 0.278 (0.533)2 ¼ 0.284
BMI ¼ body-mass index; HOMA-IR ¼ homeostasis model assessment-insulin resistance; SE ¼ standard error; SHBG ¼ sex hormone-binding globulin.
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ponectin had any influence upon LDL-C and so added adi-
ponectin as another independent variable after adjusting for
age and ln BMI, with ln LDL-C as the dependent variable.
Adiponectin, however, was still not significant in the multiple
regression model (Table 4, model 2). Due to a high correlation
between BMI and HOMA-IR, we replaced BMI with HOMA-
IR and tried to introduce HOMA-IR to the multiple regression
model. In the multiple regression model (Table 4, model 3),
using ln LDL-C as the dependent variable and adding adipo-
nectin as an independent variable after adjusting for age and ln
HOMA-IR, we still found that adiponectin was not significant.
Thus, adiponectin had no effect on LDL-C levels and should
not be included in the regression model that is used to predict
levels of LDL-C. From the results of our regression model, we
understood that adiponectin had no association with the LDL-
C level.
Similarly, adiponectin was not significantly related to the
TG level when considering other possible confounding factors,
and the TG level was mainly affected by age change and
HOMA-IR level (Table 5, model 1). In order to determine
whether adiponectin would affect TG, we introduced
a forward stepwise multiple linear regression with ln TG as the
dependent variable. Interestingly, we found that ln adiponectin
was also significant in the multiple regression model (Table 5,
model 3). Accordingly, adiponectin may not be a key point but
still plays some role in which it accompanies age changes and
HOMA-IR level in affecting the TG level. Furthermore, we
found that adiponectin as another independent variable was
also significant in a multiple regression model (Table 5, model
2) after adjusting for age and ln BMI, which replaced lnTable 5
Multiple regression analysis of logarithmically transformed (ln) TG levels (mg/dL
Taiwanese women with polycystic ovary syndrome.
Variable Model 1
r SE p r
Age (y) 0.229 0.008 0.003 0.1
Ln BMI (kg/m2) 0.096 0.250 0.408 0.3
Ln HOMA-IR 0.365 0.052 <0.001
Ln SHBG (nmol/L) 0.052 0.080 0.588
Ln adiponectin (mg/mL) 0.155 0.098 0.091 0.2
R2 (0.653)2 ¼ 0.426
BMI ¼ body-mass index; HOMA-IR ¼ homeostasis model assessment-insulin
TG ¼ total triglyceride.HOMA-IR. If we regarded the R2 value as a priority, model 3
in Table 5 would be a better choice than model 2 to predict TG
levels. Nevertheless, adiponectin produced a larger R2 value in
the model with HDL as the dependent variable compared to
that in the model with TG as the dependent variable (Tables 3
and 5). For that reason, we believe that adiponectin had
a greater influence in predicting HDL-C than TG levels.
Considering the relation between adiponectin and HDL-C, it
was reasonable to use only adiponectin and SHBG as inde-
pendent variables to predict levels of HDL, according to the
results of the forward stepwise multiple linear regression
(Table 3, model 2). Although age was not a significant variable
in the forward stepwise multiple linear regression, we
considered that age is a very important biologic character in
humans and thus added it as another independent variable. We
then found that age increased the R2 value in the model with
HDL as the dependent variable (Table 3, model 3). However,
we still deemed that it was sufficient and logical to use only
adiponectin and SHBG as independent variables to predict
HDL-C levels. Additionally, we tried to perform multiple
linear regression analysis in different BMI groups. Due to the
small number of overweight women (24  BMI < 27), we put
overweight and obese women (27  BMI) together. With ln
HDL as the dependent variable, we found that ln adiponectin
was still significant in the three different BMI groups
(Table 6), but only ln SHBG was significant in the normal-
range group.
To further investigate the effects of adiponectin on lower-
and higher-HDL-C groups, we used a logistic regression to
analyze the odds ratio (OR) between lower- and higher-HDL-
C groups with a cutoff at 50 mg/dL, which was based on) with age, ln BMI, ln HOMA-IR, ln SHBG, and ln adiponectin among 118
Model 2 Model 3
SE p r SE p
97 0.008 0.013 0.237 0.008 <0.001
45 0.199 <0.001
0.439 0.042 <0.001
35 0.099 0.012 0.194 0.091 0.019
(0.597)2 ¼ 0.357 (0.647)2 ¼ 0.419
resistance; SE ¼ standard error; SHBG ¼ sex hormone-binding globulin;
Table 6
Multiple regression analysis of logarithmically transformed (ln) HDL levels (mg/dL) with age, ln SHBG, and ln adiponectin in three different BMI groups of
Taiwanese women with polycystic ovary syndrome.
Variable BMI <18.5 18.5  BMI < 24 24  BMI
r SE p r SE p r SE p
Age (y) 0.014 0.334 0.165 <0.001 0.006 0.997 0.011 0.004 0.008
Ln SHBG (nmol/L) 0.122 0.010 0.118 0.184 0.043 <0.001 0.058 0.047 0.226
Ln adiponectin (mg/mL) 0.198 0.081 0.026 0.268 0.065 <0.001 0.212 0.053 <0.001
R2 (0.645)2 ¼ 0.416 (0.712)2 ¼ 0.506 (0.557)2 ¼ 0.310
BMI ¼ body-mass index; HDL ¼ high-density lipoprotein; SE ¼ standard error; SHBG ¼ sex hormone-binding globulin.
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adiponectin level was associated with a lower probability of an
abnormal HDL-C level (50 mg/dL), with a lower OR (0.079)
[95% confidence interval (CI) ¼ 0.015e0.412; p ¼ 0.003]
under multivariate logistic regression analyses after adjusting
for age, ln BMI, ln HOMA-IR, and ln SHBG (Table 7, model
1). Under backward stepwise multivariate logistic regression
analyses, a higher adiponectin level was still associated with
a lower probability of an abnormal HDL-C level (50 mg/dL),
with an OR of 0.88 (95% CI ¼ 0.020e0.384; p ¼ 0.001)
(Table 7, model 2). Under consideration of health modifiers in
the multivariate logistic regression analyses, we still noted that
a higher adiponectin level had a lower probability of an
abnormal HDL-C level (50 mg/dL), with an OR of 0.084
(95% CI ¼ 0.019e0.381; p ¼ 0.001) (Table 7, model 3).
Discussion
In the present study, we first demonstrate that a positive
correlation existed between serum levels of adiponectin and
HDL-C in women with PCOS. Higher levels of HDL-C were
related to increased levels of adiponectin after adjusting for
age, insulin resistance, BMI, and SHBG. In the stepwise
multiple regression analysis, we found that increasing levels of
adiponectin were prominently associated with increasing
levels of HDL-C and SHBG. In addition, we also noted that
adiponectin was negatively associated with increasing levels
of TG to some extent. These results suggest that adiponectin
may be a useful marker of the lipid status, regardless of
whether SHBG is considered or not, in women with PCOS.
PCOS patients with lower adiponectin levels should pay closeTable 7
Multivariate logistic regression with the presence of the low serum levels of high-
Variable Model 1
OR 95% CI
Age (y) 0.956 0.841e1.087
Ln BMI (kg/m2) 18.398 0.481e703.776
Ln HOMA-IR 0.540 0.227e1.284
Ln SHBG (nmol/L) 0.080* 0.020e0.325
Ln Adiponectin (mg/mL) 0.079** 0.015e0.412
Nagelkerke R2 0.549
* p < 0.001.
** p ¼ 0.003.
*** p ¼ 0.001.
BMI ¼ body-mass index; CI ¼ confidence interval; HOMA-IR ¼ homeostasis mo
binding globulin; TG ¼ total triglyceride.attention to problems of dyslipidemia. A change from
a sedentary lifestyle or weight reduction may significantly
elevate plasma adiponectin levels [14,21,22].
A positive correlation between serum levels of HDL-C and
adiponectin was also reported in patients with type-2 diabetes,
dyslipidemia, lipodystrophies, coronary heart disease, and
metabolic syndrome, and in those who are overweight
[23e29]. In nondiabetic men and in patients with type-2
diabetes, hypoadiponectinemia was found to be associated
with increased hepatic lipase activity, which may play a role in
the decreased levels of HDL-C [30]. Taken together, these
possibly indicate that there is a close or direct relationship
between adiponectin and HDL-C. However, the exact mech-
anism linking plasma adiponectin and HDL-C metabolism is
still unclear [31].
In recent studies, adiponectin was found to work through its
adipoR2 receptor to activate the peroxisome proliferator-
activated receptor (PPAR) a in mice models [32]. Activation
of PPARa was previously found to modulate the expression of
proteins that participate in HDL-C metabolism, including
apolipoprotein A-I (apoA-I), apoA-II, lipoprotein lipase,
scavenger receptor class B type I and its human homologue
(CLA-1), and adenosine triphosphate-binding cassette
transporter-1 (ABCA1) [33]. Matsuura et al [34] reported that
human recombinant adiponectin enhanced apoA-I secretion
and ABCA1 expression in a human hepatoma cell line, sug-
gesting that adiponectin might increase HDL assembly in the
liver. In adiponectin-knockout mice, Oku et al [35] found that
an adiponectin deficiency might cause impaired HDL
assembly by decreasing ABCA1 expression and apoA-I
synthesis in the liver. Further investigations are required todensity lipoprotein as the dependent variable.
Model 2 Model 3
OR 95% CI OR 95% CI
0.982 0.872e1.107
0.087* 0.026e0.291 0.087* 0.026e0.291
0.088*** 0.020e0.384 0.084*** 0.019e0.381
0.525 0.526
del assessment of insulin resistance; OR ¼ odds ratio; SHBG ¼ sex hormone-
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and HDL-C.
It was suggested that adiponectin might modulate the
endothelial inflammatory response, and hypoadiponectinemia
represent a risk factor for CAD [14,15,36]. Kumada et al [37]
found that hypoadiponectinemia in men produced a two-fold
increased risk of CAD prevalence after adjusting for other
well-known CAD risk factors. HDL-C, synthesized and
secreted from both the liver and the intestines, is the most
important lipoprotein predictor of CAD due to its preventive
effect on atherosclerosis via a major mechanism termed
reverse cholesterol transport [7,8,38]. PCOS patients with
lower adiponectin and HDL-C levels may have a higher risk
for CVD, which deserves further investigation.
High TG levels may be an independent predictor of future
risks of myocardial infarction [39] and were cited as a special
elevated cardiovascular risk factor in women [40]. Although
the exact mechanism between adiponectin and TG is still not
well understood and unclear even in women with PCOS, we
found that a negative association between adiponectin and TG
might exist, which was more or less shown by our multiple
regression model.
Recently, the concentration of serum adiponectin was
found to be stable and not affected by hyperinsulinemia, oral
glucose intake, or the fat load in the short term [41]. In
addition, the concentration of serum adiponectin appeared
similar on different days in both diabetic patients and normal
individuals [14]. Examination of serum adiponectin levels in
PCOS patients might provide information on the recent status
of lipid metabolism and over a relatively longer time.
Participants in our study were all Taiwanese, and the asso-
ciation between adiponectin and lipid profile might not be
representative of women with PCOS in other ethnic groups.
However, the high prevalence (64.4%) of low HDL-C levels
(<50 mg/dL) in women with PCOS in our study was
comparable to the prevalence (66%) documented in a recent
large multicenter study [42]. The association between adi-
ponectin levels and lipid profile deserves further studies in
other ethnic groups.
In conclusion, there was a high prevalence of low HDL-C
levels in young Taiwanese women with PCOS. Adiponectin
levels were strongly, positively, and independently related to
HDL-C levels and were also positively related to TG levels.
Hypoadiponectinemia may be a useful and more stable marker
for monitoring the status of dyslipidemia in young women
with PCOS. Adiponectin may play a role in increasing the
production of HDL-C. However, further studies are needed to
clarify the exact underlying mechanism and linkage between
adiponectin and the production of HDL-C and TGs.
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